NervGen Pharma Corp.
NGEN
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapies designed to support nervous system repair after injury or disease. The company’s lead program, NVG-291, is being studied in spinal cord injury and other neurologic conditions, while its pipeline also includes additional candidates in preclinical development. NervGen’s work centers on addressing biological barriers that limit neural recovery, with applications across neurotrauma and neurodegenerative disease areas. The company’s research and development efforts are aimed at advancing treatments for conditions such as spinal cord injury, stroke, multiple sclerosis, and amyotrophic lateral sclerosis, positioning NervGen Pharma Corp. as a specialized participant in the emerging neuroreparative medicine segment of biotechnology.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$0.00
Net Income (TTM)
-C$62M
▼ -83.8% YoY
Op. Margin
–
ROIC
-642.48%
▲ +91.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$26M
▼ -15.8% YoY
Op. Cash Flow (TTM)
-C$26M
▼ -15.8% YoY
Net Debt
-C$22M
Net Cash Position
Cash & Equiv.
C$22M
Continue Research
Peers
Biotechnology · Pick stocks to compare with NGEN
Held by ETFs
NGEN is in 1 US ETF. The largest of them, with NGEN's weight in each:
NervGen Pharma (NGEN) in three numbers
Questions about NervGen Pharma
Is NervGen Pharma a high-quality business?
NervGen Pharma scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$22M, and its weakest is return on capital at -642.5%. The Quality tab shows every check against its target.
Does NervGen Pharma (NGEN) pay a dividend?
No. NervGen Pharma (NGEN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NGEN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.